Radiopharm Theranostics Ltd (RADX) Form 6-K — Jul 31, 2026
Radiopharm Theranostics announced positive results from the Phase 2b clinical trial of its imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint of concordance with MRI imaging. The company plans to initiate a Phase 3 registrational trial for RAD 101 in Q4 2026, supported by a manufacturing and distribution partnership with Siemens Healthineers. Financial results for the quarter revealed a closing cash balance of $4.1 million, down from $19.2 million in the prior quarter, with net operating cash outflows of $14.97 million driven primarily by R&D and staff costs.
Key figures
- Cash Position
- 4100000
- Rd Tax Incentive
- 5900000
- Prior Quarter Cash
- 19200000
- Quarterly Cash Burn
- 14970000
- Atm Facility Capacity
- 18900000
- Post Quarter Share Purchase Plan
- 6000000
- Rad101 Primary Endpoint Success
- 93%
- Rad204 Partial Response Percent
- 43%
- Post Quarter Institutional Raise
- 12500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.